Market Overview

United-Guardian Reports Strong Second Quarter Sales & Earnings

Share:

HAUPPAUGE, N.Y., Aug. 08, 2018 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported today that sales and earnings for the second quarter and first six months of 2018 were both very strong, with gross sales for the first six months of the year up 15% from $6,764,379 in 2017 to $7,808,346 this year, and net income up 41% from $1,738,584 ($0.38 per share) in 2017 to $2,452,524 ($0.53) this year. Second quarter sales increased by 6% from $3,891,656 in 2017 to $4,141,399 this year, and net income for the quarter increased by 26% from $1,104,149 ($0.24 per share) in 2017 to $1,392,662 ($0.30 per share) this year.

Ken Globus, President of United-Guardian, stated, "We are pleased to report that in the first six months of the year we experienced increases in all of our product lines, with the most substantial increases coming from higher sales of our cosmetic ingredients, which increased by 18%, and stronger sales of Renacidin® Irrigation, our largest pharmaceutical product, which increased by 22%. The increase in sales of our cosmetic ingredients was primarily the result of an increase in sales of our Lubrajel® products into China, which has been a growing market for us. Our ability to continue to increase our sales in China will depend partly on what happens with the tariff situation. While the financial impact of the tariffs was relatively minor for us this quarter, it is likely that they will have a more significant impact in the future if they are fully implemented. We are working closely with our marketing partner in China to minimize the potential impact of these tariffs, and remain hopeful that despite the tariff situation we will be able to continue to increase our sales in China, and, along with our new web-based marketing campaign for Renacidin, are optimistic that we will be able to continue the excellent year we have had to date."

United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.

Contact:
Robert S. Rubinger
Public Relations
(631) 273-0900

NOTE:   This press release contains both historical and "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements about the company's expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the "safe harbor" provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company's business please refer to the company's reports and filings with the Securities and Exchange Commission.

   
RESULTS FOR THE QUARTERS ENDED
JUNE 30, 2018 and JUNE 30, 2017*
 
   
STATEMENTS OF INCOME
(UNAUDITED)
 
   
    THREE MONTHS ENDED
JUNE 30,
      SIX MONTHS ENDED 
JUNE 30,
 
    2018       2017         2018       2017  
                                 
Sales:                                
Gross sales­­­ $ 4,141,399     $ 3,891,656       $ 7,808,346     $ 6,764,379  
Sales allowances and returns   (182,181 )     (116,905 )       (329,616 )     (203,240 )
Net Sales   3,959,218       3,774,751         7,478,730       6,561,139  
                                 
Costs and expenses:                                
Cost of sales   1,610,173       1,667,113         3,061,104       2,931,209  
Operating expenses   534,420       418,605         1,058,534       882,085  
Research and development   91,285       158,275         192,949       348,004  
Total costs and expenses   2,235,878       2,243,993         4,312,587       4,161,298  
Income from operations   1,723,340       1,530,758         3,166,143       2,399,841  
                                 
Other income (expense):                                
Investment income   57,777       68,690         104,559       121,562  
Unrealized gain (loss) on marketable
   securities
  95,020       ---         (40,130 )     ---  
Realized (loss) gain on marketable
    securities
  (113,276 )     4,106         (113,276 )     4,106  
Loss on trade-in of equipment   ---       ---         (12,837 )     ---  
Total other income (expense)   39,521       72,796         (61,684       125,668  
Income before provision for
 income taxes
  1,762,861       1,603,554         3,104,459       2,525,509  
Provision for income taxes   370,199       499,405         651,935       786,925  
Net Income $ 1,392,662     $ 1,104,149       $ 2,452,524     $ 1,738,584  
 Earnings per common share                                
(basic and diluted) $ 0.30     $ 0.24       $ 0.53     $ 0.38  
                                 
Weighted average shares – basic and diluted   4,594,319       4,594,319         4,594,319       4,594,319  
                                 

* Additional financial information can be found at the company's web site at www.u-g.com.

Primary Logo

View Comments and Join the Discussion!